nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketamine—CYP2C8—Tazarotene—psoriasis	0.107	0.138	CbGbCtD
Ketamine—CYP2B6—Cholecalciferol—psoriasis	0.0603	0.0779	CbGbCtD
Ketamine—CYP2C8—Cholecalciferol—psoriasis	0.0457	0.059	CbGbCtD
Ketamine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0396	0.0511	CbGbCtD
Ketamine—CYP3A4—Calcitriol—psoriasis	0.0359	0.0464	CbGbCtD
Ketamine—CYP2C9—Cholecalciferol—psoriasis	0.0318	0.0411	CbGbCtD
Ketamine—CYP2C8—Hydrocortisone—psoriasis	0.0318	0.041	CbGbCtD
Ketamine—CYP2C8—Cyclosporine—psoriasis	0.03	0.0388	CbGbCtD
Ketamine—CYP3A4—Methoxsalen—psoriasis	0.028	0.0361	CbGbCtD
Ketamine—ABCB1—Mycophenolate mofetil—psoriasis	0.0268	0.0346	CbGbCtD
Ketamine—CYP2B6—Dexamethasone—psoriasis	0.0261	0.0337	CbGbCtD
Ketamine—ABCB1—Betamethasone—psoriasis	0.023	0.0297	CbGbCtD
Ketamine—ABCB1—Prednisolone—psoriasis	0.0227	0.0293	CbGbCtD
Ketamine—ABCB1—Hydrocortisone—psoriasis	0.0215	0.0278	CbGbCtD
Ketamine—ABCB1—Prednisone—psoriasis	0.0214	0.0277	CbGbCtD
Ketamine—CYP2C9—Cyclosporine—psoriasis	0.0209	0.027	CbGbCtD
Ketamine—ABCB1—Cyclosporine—psoriasis	0.0203	0.0262	CbGbCtD
Ketamine—CYP2C8—Dexamethasone—psoriasis	0.0198	0.0255	CbGbCtD
Ketamine—CYP3A4—Cholecalciferol—psoriasis	0.0185	0.0239	CbGbCtD
Ketamine—CYP3A4—Triamcinolone—psoriasis	0.0161	0.0207	CbGbCtD
Ketamine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0161	0.0207	CbGbCtD
Ketamine—CYP2C9—Dexamethasone—psoriasis	0.0138	0.0178	CbGbCtD
Ketamine—CYP3A4—Betamethasone—psoriasis	0.0138	0.0178	CbGbCtD
Ketamine—CYP3A4—Prednisolone—psoriasis	0.0136	0.0176	CbGbCtD
Ketamine—ABCB1—Dexamethasone—psoriasis	0.0134	0.0173	CbGbCtD
Ketamine—CYP3A4—Hydrocortisone—psoriasis	0.0129	0.0166	CbGbCtD
Ketamine—CYP3A4—Prednisone—psoriasis	0.0128	0.0166	CbGbCtD
Ketamine—CYP3A4—Cyclosporine—psoriasis	0.0122	0.0157	CbGbCtD
Ketamine—ABCB1—Methotrexate—psoriasis	0.0107	0.0139	CbGbCtD
Ketamine—CYP3A4—Dexamethasone—psoriasis	0.00801	0.0103	CbGbCtD
Ketamine—Obstructive airways disorder—Methotrexate—psoriasis	0.00354	0.0221	CcSEcCtD
Ketamine—Epilepsy—Hydrocortisone—psoriasis	0.0034	0.0212	CcSEcCtD
Ketamine—Erythema—Calcipotriol—psoriasis	0.00339	0.0212	CcSEcCtD
Ketamine—Epilepsy—Betamethasone—psoriasis	0.0029	0.0182	CcSEcCtD
Ketamine—Epilepsy—Dexamethasone—psoriasis	0.0029	0.0182	CcSEcCtD
Ketamine—Salivary hypersecretion—Acitretin—psoriasis	0.00265	0.0166	CcSEcCtD
Ketamine—Epilepsy—Prednisone—psoriasis	0.00253	0.0158	CcSEcCtD
Ketamine—Erythema—Tazarotene—psoriasis	0.0025	0.0156	CcSEcCtD
Ketamine—Pain—Calcipotriol—psoriasis	0.00236	0.0148	CcSEcCtD
Ketamine—Apnoea—Mycophenolic acid—psoriasis	0.00212	0.0133	CcSEcCtD
Ketamine—Erythema—Clobetasol propionate—psoriasis	0.00212	0.0132	CcSEcCtD
Ketamine—Nystagmus—Mycophenolate mofetil—psoriasis	0.00199	0.0124	CcSEcCtD
Ketamine—Diplopia—Acitretin—psoriasis	0.00198	0.0124	CcSEcCtD
Ketamine—Diplopia—Fluocinolone Acetonide—psoriasis	0.00198	0.0124	CcSEcCtD
Ketamine—Erythema—Fluocinonide—psoriasis	0.00191	0.0119	CcSEcCtD
Ketamine—Laryngospasm—Mycophenolate mofetil—psoriasis	0.0019	0.0119	CcSEcCtD
Ketamine—Rash—Calcipotriol—psoriasis	0.00174	0.0109	CcSEcCtD
Ketamine—Pain—Tazarotene—psoriasis	0.00174	0.0109	CcSEcCtD
Ketamine—Dermatitis—Calcipotriol—psoriasis	0.00174	0.0109	CcSEcCtD
Ketamine—Apnoea—Mycophenolate mofetil—psoriasis	0.00167	0.0105	CcSEcCtD
Ketamine—Bladder pain—Mycophenolic acid—psoriasis	0.00162	0.0102	CcSEcCtD
Ketamine—Anaphylactic shock—Beclomethasone—psoriasis	0.00157	0.00983	CcSEcCtD
Ketamine—Arrhythmia—Methoxsalen—psoriasis	0.00155	0.00967	CcSEcCtD
Ketamine—Erythema—Methoxsalen—psoriasis	0.00151	0.00942	CcSEcCtD
Ketamine—Pain—Clobetasol propionate—psoriasis	0.00148	0.00923	CcSEcCtD
Ketamine—Cystitis noninfective—Mycophenolate mofetil—psoriasis	0.00139	0.00866	CcSEcCtD
Ketamine—Arrhythmia—Calcitriol—psoriasis	0.00138	0.00862	CcSEcCtD
Ketamine—Cystitis—Mycophenolate mofetil—psoriasis	0.00137	0.00856	CcSEcCtD
Ketamine—Pain—Beclomethasone—psoriasis	0.00134	0.00841	CcSEcCtD
Ketamine—Erythema—Calcitriol—psoriasis	0.00134	0.0084	CcSEcCtD
Ketamine—Pain—Fluocinonide—psoriasis	0.00133	0.00833	CcSEcCtD
Ketamine—Rash—Tazarotene—psoriasis	0.00128	0.00803	CcSEcCtD
Ketamine—Dermatitis—Tazarotene—psoriasis	0.00128	0.00802	CcSEcCtD
Ketamine—Bladder pain—Mycophenolate mofetil—psoriasis	0.00128	0.00802	CcSEcCtD
Ketamine—Erythema—Acitretin—psoriasis	0.00119	0.00747	CcSEcCtD
Ketamine—Erythema—Fluocinolone Acetonide—psoriasis	0.00119	0.00745	CcSEcCtD
Ketamine—Convulsion—Calcitriol—psoriasis	0.00116	0.00727	CcSEcCtD
Ketamine—Hypotension—Methoxsalen—psoriasis	0.00115	0.00718	CcSEcCtD
Ketamine—Vision blurred—Acitretin—psoriasis	0.00113	0.00704	CcSEcCtD
Ketamine—Vision blurred—Fluocinolone Acetonide—psoriasis	0.00112	0.00702	CcSEcCtD
Ketamine—Anaphylactic shock—Calcitriol—psoriasis	0.0011	0.00685	CcSEcCtD
Ketamine—Rash—Clobetasol propionate—psoriasis	0.00109	0.00681	CcSEcCtD
Ketamine—Dermatitis—Clobetasol propionate—psoriasis	0.00109	0.0068	CcSEcCtD
Ketamine—Anorexia—Calcitriol—psoriasis	0.00104	0.00653	CcSEcCtD
Ketamine—Diplopia—Mycophenolate mofetil—psoriasis	0.00103	0.00644	CcSEcCtD
Ketamine—Rash—Beclomethasone—psoriasis	0.000992	0.0062	CcSEcCtD
Ketamine—Dermatitis—Beclomethasone—psoriasis	0.000991	0.00619	CcSEcCtD
Ketamine—Rash—Fluocinonide—psoriasis	0.000982	0.00614	CcSEcCtD
Ketamine—Dermatitis—Fluocinonide—psoriasis	0.000982	0.00614	CcSEcCtD
Ketamine—Decreased appetite—Calcitriol—psoriasis	0.000953	0.00596	CcSEcCtD
Ketamine—Apnoea—Methotrexate—psoriasis	0.000948	0.00592	CcSEcCtD
Ketamine—Erythema—Hydroxyurea—psoriasis	0.000938	0.00586	CcSEcCtD
Ketamine—Pain—Calcitriol—psoriasis	0.000937	0.00586	CcSEcCtD
Ketamine—Nausea—Beclomethasone—psoriasis	0.000934	0.00584	CcSEcCtD
Ketamine—Anorexia—Acitretin—psoriasis	0.00093	0.00581	CcSEcCtD
Ketamine—Bradycardia—Mycophenolic acid—psoriasis	0.000919	0.00574	CcSEcCtD
Ketamine—Decreased appetite—Acitretin—psoriasis	0.000848	0.0053	CcSEcCtD
Ketamine—Pain—Acitretin—psoriasis	0.000834	0.00521	CcSEcCtD
Ketamine—Pain—Fluocinolone Acetonide—psoriasis	0.000832	0.0052	CcSEcCtD
Ketamine—Convulsion—Hydroxyurea—psoriasis	0.000813	0.00508	CcSEcCtD
Ketamine—Arrhythmia—Mycophenolic acid—psoriasis	0.000806	0.00504	CcSEcCtD
Ketamine—Cystitis noninfective—Methotrexate—psoriasis	0.000785	0.00491	CcSEcCtD
Ketamine—Cystitis—Methotrexate—psoriasis	0.000776	0.00485	CcSEcCtD
Ketamine—Rash—Methoxsalen—psoriasis	0.000775	0.00485	CcSEcCtD
Ketamine—Dermatitis—Methoxsalen—psoriasis	0.000775	0.00484	CcSEcCtD
Ketamine—Vision blurred—Mycophenolic acid—psoriasis	0.00074	0.00463	CcSEcCtD
Ketamine—Nausea—Methoxsalen—psoriasis	0.000731	0.00457	CcSEcCtD
Ketamine—Anorexia—Hydroxyurea—psoriasis	0.00073	0.00456	CcSEcCtD
Ketamine—Bladder pain—Methotrexate—psoriasis	0.000726	0.00454	CcSEcCtD
Ketamine—Bradycardia—Mycophenolate mofetil—psoriasis	0.000725	0.00453	CcSEcCtD
Ketamine—Vomiting—Calcitriol—psoriasis	0.000697	0.00436	CcSEcCtD
Ketamine—Rash—Calcitriol—psoriasis	0.000691	0.00432	CcSEcCtD
Ketamine—Dermatitis—Calcitriol—psoriasis	0.000691	0.00432	CcSEcCtD
Ketamine—Convulsion—Mycophenolic acid—psoriasis	0.000681	0.00425	CcSEcCtD
Ketamine—Bradycardia—Prednisolone—psoriasis	0.000676	0.00423	CcSEcCtD
Ketamine—Decreased appetite—Hydroxyurea—psoriasis	0.000666	0.00416	CcSEcCtD
Ketamine—Bradycardia—Hydrocortisone—psoriasis	0.000661	0.00413	CcSEcCtD
Ketamine—Pain—Hydroxyurea—psoriasis	0.000655	0.00409	CcSEcCtD
Ketamine—Arrhythmia—Cyclosporine—psoriasis	0.000652	0.00408	CcSEcCtD
Ketamine—Nausea—Calcitriol—psoriasis	0.000651	0.00407	CcSEcCtD
Ketamine—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000636	0.00398	CcSEcCtD
Ketamine—Shock—Mycophenolic acid—psoriasis	0.000631	0.00394	CcSEcCtD
Ketamine—Bradycardia—Triamcinolone—psoriasis	0.000622	0.00389	CcSEcCtD
Ketamine—Vomiting—Acitretin—psoriasis	0.00062	0.00388	CcSEcCtD
Ketamine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000618	0.00386	CcSEcCtD
Ketamine—Rash—Acitretin—psoriasis	0.000615	0.00384	CcSEcCtD
Ketamine—Dermatitis—Acitretin—psoriasis	0.000614	0.00384	CcSEcCtD
Ketamine—Rash—Fluocinolone Acetonide—psoriasis	0.000613	0.00383	CcSEcCtD
Ketamine—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000613	0.00383	CcSEcCtD
Ketamine—Anorexia—Mycophenolic acid—psoriasis	0.000611	0.00382	CcSEcCtD
Ketamine—Hypotension—Mycophenolic acid—psoriasis	0.000599	0.00375	CcSEcCtD
Ketamine—Vision blurred—Cyclosporine—psoriasis	0.000599	0.00374	CcSEcCtD
Ketamine—Arrhythmia—Prednisolone—psoriasis	0.000594	0.00371	CcSEcCtD
Ketamine—Arrhythmia—Hydrocortisone—psoriasis	0.00058	0.00362	CcSEcCtD
Ketamine—Nausea—Acitretin—psoriasis	0.000579	0.00362	CcSEcCtD
Ketamine—Erythema—Prednisolone—psoriasis	0.000578	0.00362	CcSEcCtD
Ketamine—Nausea—Fluocinolone Acetonide—psoriasis	0.000578	0.00361	CcSEcCtD
Ketamine—Erythema—Hydrocortisone—psoriasis	0.000565	0.00353	CcSEcCtD
Ketamine—Bradycardia—Betamethasone—psoriasis	0.000564	0.00353	CcSEcCtD
Ketamine—Bradycardia—Dexamethasone—psoriasis	0.000564	0.00353	CcSEcCtD
Ketamine—Decreased appetite—Mycophenolic acid—psoriasis	0.000557	0.00348	CcSEcCtD
Ketamine—Convulsion—Cyclosporine—psoriasis	0.000551	0.00344	CcSEcCtD
Ketamine—Pain—Mycophenolic acid—psoriasis	0.000548	0.00343	CcSEcCtD
Ketamine—Arrhythmia—Triamcinolone—psoriasis	0.000546	0.00341	CcSEcCtD
Ketamine—Vision blurred—Prednisolone—psoriasis	0.000545	0.00341	CcSEcCtD
Ketamine—Convulsion—Mycophenolate mofetil—psoriasis	0.000537	0.00336	CcSEcCtD
Ketamine—Erythema—Triamcinolone—psoriasis	0.000532	0.00332	CcSEcCtD
Ketamine—Anaphylactic shock—Cyclosporine—psoriasis	0.000519	0.00324	CcSEcCtD
Ketamine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000506	0.00316	CcSEcCtD
Ketamine—Convulsion—Prednisolone—psoriasis	0.000501	0.00313	CcSEcCtD
Ketamine—Shock—Mycophenolate mofetil—psoriasis	0.000498	0.00311	CcSEcCtD
Ketamine—Arrhythmia—Betamethasone—psoriasis	0.000495	0.0031	CcSEcCtD
Ketamine—Arrhythmia—Dexamethasone—psoriasis	0.000495	0.0031	CcSEcCtD
Ketamine—Anorexia—Cyclosporine—psoriasis	0.000494	0.00309	CcSEcCtD
Ketamine—Bradycardia—Prednisone—psoriasis	0.000492	0.00307	CcSEcCtD
Ketamine—Convulsion—Hydrocortisone—psoriasis	0.000489	0.00306	CcSEcCtD
Ketamine—Vomiting—Hydroxyurea—psoriasis	0.000487	0.00304	CcSEcCtD
Ketamine—Rash—Hydroxyurea—psoriasis	0.000483	0.00302	CcSEcCtD
Ketamine—Erythema—Dexamethasone—psoriasis	0.000483	0.00302	CcSEcCtD
Ketamine—Erythema—Betamethasone—psoriasis	0.000483	0.00302	CcSEcCtD
Ketamine—Anorexia—Mycophenolate mofetil—psoriasis	0.000482	0.00302	CcSEcCtD
Ketamine—Dermatitis—Hydroxyurea—psoriasis	0.000482	0.00301	CcSEcCtD
Ketamine—Hypotension—Mycophenolate mofetil—psoriasis	0.000473	0.00296	CcSEcCtD
Ketamine—Anaphylactic shock—Prednisolone—psoriasis	0.000472	0.00295	CcSEcCtD
Ketamine—Shock—Prednisolone—psoriasis	0.000464	0.0029	CcSEcCtD
Ketamine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000461	0.00288	CcSEcCtD
Ketamine—Convulsion—Triamcinolone—psoriasis	0.000461	0.00288	CcSEcCtD
Ketamine—Nausea—Hydroxyurea—psoriasis	0.000455	0.00284	CcSEcCtD
Ketamine—Shock—Hydrocortisone—psoriasis	0.000454	0.00284	CcSEcCtD
Ketamine—Decreased appetite—Cyclosporine—psoriasis	0.000451	0.00282	CcSEcCtD
Ketamine—Pain—Cyclosporine—psoriasis	0.000444	0.00277	CcSEcCtD
Ketamine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00044	0.00275	CcSEcCtD
Ketamine—Anorexia—Hydrocortisone—psoriasis	0.000439	0.00275	CcSEcCtD
Ketamine—Anaphylactic shock—Triamcinolone—psoriasis	0.000434	0.00271	CcSEcCtD
Ketamine—Pain—Mycophenolate mofetil—psoriasis	0.000433	0.0027	CcSEcCtD
Ketamine—Arrhythmia—Prednisone—psoriasis	0.000431	0.0027	CcSEcCtD
Ketamine—Hypotension—Hydrocortisone—psoriasis	0.000431	0.00269	CcSEcCtD
Ketamine—Shock—Triamcinolone—psoriasis	0.000427	0.00267	CcSEcCtD
Ketamine—Erythema—Prednisone—psoriasis	0.00042	0.00263	CcSEcCtD
Ketamine—Convulsion—Betamethasone—psoriasis	0.000418	0.00261	CcSEcCtD
Ketamine—Convulsion—Dexamethasone—psoriasis	0.000418	0.00261	CcSEcCtD
Ketamine—Vomiting—Mycophenolic acid—psoriasis	0.000408	0.00255	CcSEcCtD
Ketamine—Rash—Mycophenolic acid—psoriasis	0.000404	0.00253	CcSEcCtD
Ketamine—Dermatitis—Mycophenolic acid—psoriasis	0.000404	0.00252	CcSEcCtD
Ketamine—Pain—Prednisolone—psoriasis	0.000404	0.00252	CcSEcCtD
Ketamine—Decreased appetite—Hydrocortisone—psoriasis	0.000401	0.0025	CcSEcCtD
Ketamine—Vision blurred—Prednisone—psoriasis	0.000396	0.00248	CcSEcCtD
Ketamine—Pain—Hydrocortisone—psoriasis	0.000394	0.00246	CcSEcCtD
Ketamine—Anaphylactic shock—Dexamethasone—psoriasis	0.000394	0.00246	CcSEcCtD
Ketamine—Anaphylactic shock—Betamethasone—psoriasis	0.000394	0.00246	CcSEcCtD
Ketamine—Shock—Betamethasone—psoriasis	0.000388	0.00242	CcSEcCtD
Ketamine—Shock—Dexamethasone—psoriasis	0.000388	0.00242	CcSEcCtD
Ketamine—Nausea—Mycophenolic acid—psoriasis	0.000381	0.00238	CcSEcCtD
Ketamine—Anorexia—Dexamethasone—psoriasis	0.000375	0.00235	CcSEcCtD
Ketamine—Anorexia—Betamethasone—psoriasis	0.000375	0.00235	CcSEcCtD
Ketamine—Pain—Triamcinolone—psoriasis	0.000371	0.00232	CcSEcCtD
Ketamine—Hypotension—Betamethasone—psoriasis	0.000368	0.0023	CcSEcCtD
Ketamine—Hypotension—Dexamethasone—psoriasis	0.000368	0.0023	CcSEcCtD
Ketamine—Convulsion—Prednisone—psoriasis	0.000364	0.00228	CcSEcCtD
Ketamine—Erythema—Methotrexate—psoriasis	0.000351	0.0022	CcSEcCtD
Ketamine—Anaphylactic shock—Prednisone—psoriasis	0.000343	0.00214	CcSEcCtD
Ketamine—Decreased appetite—Dexamethasone—psoriasis	0.000342	0.00214	CcSEcCtD
Ketamine—Decreased appetite—Betamethasone—psoriasis	0.000342	0.00214	CcSEcCtD
Ketamine—Shock—Prednisone—psoriasis	0.000337	0.00211	CcSEcCtD
Ketamine—Pain—Betamethasone—psoriasis	0.000337	0.00211	CcSEcCtD
Ketamine—Pain—Dexamethasone—psoriasis	0.000337	0.00211	CcSEcCtD
Ketamine—Vision blurred—Methotrexate—psoriasis	0.000331	0.00207	CcSEcCtD
Ketamine—Vomiting—Cyclosporine—psoriasis	0.00033	0.00206	CcSEcCtD
Ketamine—Rash—Cyclosporine—psoriasis	0.000327	0.00204	CcSEcCtD
Ketamine—Anorexia—Prednisone—psoriasis	0.000327	0.00204	CcSEcCtD
Ketamine—Dermatitis—Cyclosporine—psoriasis	0.000327	0.00204	CcSEcCtD
Ketamine—Vomiting—Mycophenolate mofetil—psoriasis	0.000322	0.00201	CcSEcCtD
Ketamine—Rash—Mycophenolate mofetil—psoriasis	0.000319	0.00199	CcSEcCtD
Ketamine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000319	0.00199	CcSEcCtD
Ketamine—Nausea—Cyclosporine—psoriasis	0.000308	0.00193	CcSEcCtD
Ketamine—Convulsion—Methotrexate—psoriasis	0.000304	0.0019	CcSEcCtD
Ketamine—Nausea—Mycophenolate mofetil—psoriasis	0.000301	0.00188	CcSEcCtD
Ketamine—Decreased appetite—Prednisone—psoriasis	0.000298	0.00186	CcSEcCtD
Ketamine—Rash—Prednisolone—psoriasis	0.000298	0.00186	CcSEcCtD
Ketamine—Dermatitis—Prednisolone—psoriasis	0.000297	0.00186	CcSEcCtD
Ketamine—Vomiting—Hydrocortisone—psoriasis	0.000293	0.00183	CcSEcCtD
Ketamine—Rash—Hydrocortisone—psoriasis	0.000291	0.00182	CcSEcCtD
Ketamine—Dermatitis—Hydrocortisone—psoriasis	0.00029	0.00182	CcSEcCtD
Ketamine—Anaphylactic shock—Methotrexate—psoriasis	0.000287	0.00179	CcSEcCtD
Ketamine—Nausea—Prednisolone—psoriasis	0.00028	0.00175	CcSEcCtD
Ketamine—Vomiting—Triamcinolone—psoriasis	0.000276	0.00173	CcSEcCtD
Ketamine—Nausea—Hydrocortisone—psoriasis	0.000274	0.00171	CcSEcCtD
Ketamine—Rash—Triamcinolone—psoriasis	0.000274	0.00171	CcSEcCtD
Ketamine—Dermatitis—Triamcinolone—psoriasis	0.000273	0.00171	CcSEcCtD
Ketamine—Anorexia—Methotrexate—psoriasis	0.000273	0.00171	CcSEcCtD
Ketamine—Hypotension—Methotrexate—psoriasis	0.000268	0.00167	CcSEcCtD
Ketamine—Nausea—Triamcinolone—psoriasis	0.000258	0.00161	CcSEcCtD
Ketamine—Vomiting—Dexamethasone—psoriasis	0.00025	0.00157	CcSEcCtD
Ketamine—Vomiting—Betamethasone—psoriasis	0.00025	0.00157	CcSEcCtD
Ketamine—Decreased appetite—Methotrexate—psoriasis	0.000249	0.00156	CcSEcCtD
Ketamine—Rash—Betamethasone—psoriasis	0.000248	0.00155	CcSEcCtD
Ketamine—Rash—Dexamethasone—psoriasis	0.000248	0.00155	CcSEcCtD
Ketamine—Dermatitis—Dexamethasone—psoriasis	0.000248	0.00155	CcSEcCtD
Ketamine—Dermatitis—Betamethasone—psoriasis	0.000248	0.00155	CcSEcCtD
Ketamine—Pain—Methotrexate—psoriasis	0.000245	0.00153	CcSEcCtD
Ketamine—Nausea—Betamethasone—psoriasis	0.000234	0.00146	CcSEcCtD
Ketamine—Nausea—Dexamethasone—psoriasis	0.000234	0.00146	CcSEcCtD
Ketamine—Vomiting—Prednisone—psoriasis	0.000218	0.00136	CcSEcCtD
Ketamine—Rash—Prednisone—psoriasis	0.000216	0.00135	CcSEcCtD
Ketamine—Dermatitis—Prednisone—psoriasis	0.000216	0.00135	CcSEcCtD
Ketamine—Nausea—Prednisone—psoriasis	0.000204	0.00127	CcSEcCtD
Ketamine—Vomiting—Methotrexate—psoriasis	0.000182	0.00114	CcSEcCtD
Ketamine—Rash—Methotrexate—psoriasis	0.000181	0.00113	CcSEcCtD
Ketamine—Dermatitis—Methotrexate—psoriasis	0.000181	0.00113	CcSEcCtD
Ketamine—Nausea—Methotrexate—psoriasis	0.00017	0.00106	CcSEcCtD
Ketamine—TACR1—SIDS Susceptibility Pathways—TNF—psoriasis	0.000132	0.00201	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000131	0.00199	CbGpPWpGaD
Ketamine—GRIN1—BDNF signaling pathway—JUN—psoriasis	0.00013	0.00197	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000129	0.00197	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CCL20—psoriasis	0.000128	0.00195	CbGpPWpGaD
Ketamine—OPRM1—TCR Signaling Pathway—CD4—psoriasis	0.000128	0.00194	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000127	0.00194	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—HCAR2—psoriasis	0.000127	0.00192	CbGpPWpGaD
Ketamine—GRIN2B—BDNF signaling pathway—JUN—psoriasis	0.000127	0.00192	CbGpPWpGaD
Ketamine—GRIN1—BDNF signaling pathway—NFKB1—psoriasis	0.000125	0.0019	CbGpPWpGaD
Ketamine—GRIN2B—BDNF signaling pathway—NFKB1—psoriasis	0.000122	0.00185	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—JUN—psoriasis	0.000122	0.00185	CbGpPWpGaD
Ketamine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000118	0.00179	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IL10—psoriasis	0.000117	0.00178	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000117	0.00178	CbGpPWpGaD
Ketamine—OPRM1—TCR Signaling Pathway—JUN—psoriasis	0.000114	0.00174	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IL4—psoriasis	0.000114	0.00173	CbGpPWpGaD
Ketamine—GRIN1—Spinal Cord Injury—TNF—psoriasis	0.000114	0.00173	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	0.000112	0.00171	CbGpPWpGaD
Ketamine—GRIN1—BDNF signaling pathway—STAT3—psoriasis	0.000112	0.00171	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—HLA-B—psoriasis	0.000111	0.00169	CbGpPWpGaD
Ketamine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000111	0.00169	CbGpPWpGaD
Ketamine—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	0.00011	0.00167	CbGpPWpGaD
Ketamine—GRIN2B—BDNF signaling pathway—STAT3—psoriasis	0.000109	0.00166	CbGpPWpGaD
Ketamine—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000109	0.00165	CbGpPWpGaD
Ketamine—TACR1—SIDS Susceptibility Pathways—IL6—psoriasis	0.000107	0.00162	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000106	0.00162	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—HCAR2—psoriasis	0.000106	0.0016	CbGpPWpGaD
Ketamine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000104	0.00158	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—HLA-A—psoriasis	0.000103	0.00157	CbGpPWpGaD
Ketamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000102	0.00154	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—HCAR2—psoriasis	0.000101	0.00153	CbGpPWpGaD
Ketamine—GRIN1—Spinal Cord Injury—TP53—psoriasis	0.0001	0.00153	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CCL20—psoriasis	9.76e-05	0.00148	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCL20—psoriasis	9.7e-05	0.00148	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—HCAR2—psoriasis	9.59e-05	0.00146	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	9.44e-05	0.00143	CbGpPWpGaD
Ketamine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	9.41e-05	0.00143	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	9.35e-05	0.00142	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCL20—psoriasis	9.3e-05	0.00141	CbGpPWpGaD
Ketamine—GRIN1—Spinal Cord Injury—IL6—psoriasis	9.2e-05	0.0014	CbGpPWpGaD
Ketamine—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	9.13e-05	0.00139	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—TNF—psoriasis	9.11e-05	0.00139	CbGpPWpGaD
Ketamine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	8.98e-05	0.00136	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCL20—psoriasis	8.87e-05	0.00135	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—HCAR2—psoriasis	8.84e-05	0.00134	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TAGAP—psoriasis	8.74e-05	0.00133	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CCL20—psoriasis	8.56e-05	0.0013	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—TYK2—psoriasis	8.38e-05	0.00127	CbGpPWpGaD
Ketamine—TACR1—GPCR ligand binding—CXCL8—psoriasis	8.28e-05	0.00126	CbGpPWpGaD
Ketamine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	8.25e-05	0.00125	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—TYK2—psoriasis	8.17e-05	0.00124	CbGpPWpGaD
Ketamine—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	8.01e-05	0.00122	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—NDUFA5—psoriasis	7.92e-05	0.0012	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—LEP—psoriasis	7.83e-05	0.00119	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCL20—psoriasis	7.78e-05	0.00118	CbGpPWpGaD
Ketamine—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	7.71e-05	0.00117	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TAGAP—psoriasis	7.67e-05	0.00117	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—LEP—psoriasis	7.64e-05	0.00116	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—HCAR2—psoriasis	7.47e-05	0.00114	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.39e-05	0.00112	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—LEP—psoriasis	7.38e-05	0.00112	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—IL6—psoriasis	7.35e-05	0.00112	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	7.27e-05	0.00111	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CCL20—psoriasis	7.24e-05	0.0011	CbGpPWpGaD
Ketamine—OPRM1—TCR Signaling Pathway—IL6—psoriasis	6.91e-05	0.00105	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IFNG—psoriasis	6.89e-05	0.00105	CbGpPWpGaD
Ketamine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	6.88e-05	0.00105	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—NOS2—psoriasis	6.88e-05	0.00105	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—PPARG—psoriasis	6.82e-05	0.00104	CbGpPWpGaD
Ketamine—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	6.77e-05	0.00103	CbGpPWpGaD
Ketamine—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	6.76e-05	0.00103	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—CYP2S1—psoriasis	6.74e-05	0.00102	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—PPARG—psoriasis	6.65e-05	0.00101	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCL20—psoriasis	6.57e-05	0.000999	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TAGAP—psoriasis	6.48e-05	0.000985	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—PPARG—psoriasis	6.43e-05	0.000977	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—CXCL8—psoriasis	6.41e-05	0.000974	CbGpPWpGaD
Ketamine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.13e-05	0.000931	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—NDUFA5—psoriasis	6.05e-05	0.000919	CbGpPWpGaD
Ketamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.01e-05	0.000914	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—TYK2—psoriasis	5.98e-05	0.000909	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—VEGFA—psoriasis	5.93e-05	0.000901	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.87e-05	0.000892	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—TYK2—psoriasis	5.83e-05	0.000886	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—VEGFA—psoriasis	5.78e-05	0.000878	CbGpPWpGaD
Ketamine—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	5.71e-05	0.000868	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—HCAR2—psoriasis	5.66e-05	0.000861	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CCL20—psoriasis	5.48e-05	0.000834	CbGpPWpGaD
Ketamine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.37e-05	0.000817	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.28e-05	0.000802	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCL20—psoriasis	5.24e-05	0.000796	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—VEGFA—psoriasis	5.21e-05	0.000791	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CYP2S1—psoriasis	5.14e-05	0.000781	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—SOCS1—psoriasis	5.12e-05	0.000778	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—NDUFA5—psoriasis	5.12e-05	0.000778	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCL20—psoriasis	4.98e-05	0.000757	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TAGAP—psoriasis	4.91e-05	0.000746	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—TYK2—psoriasis	4.88e-05	0.000742	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.77e-05	0.000725	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CXCL8—psoriasis	4.68e-05	0.000712	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—CXCL8—psoriasis	4.67e-05	0.000709	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—NFKB1—psoriasis	4.66e-05	0.000708	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCL20—psoriasis	4.59e-05	0.000698	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—JUN—psoriasis	4.56e-05	0.000693	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—NFKB1—psoriasis	4.54e-05	0.00069	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.54e-05	0.00069	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—TNF—psoriasis	4.46e-05	0.000678	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—NDUFA5—psoriasis	4.46e-05	0.000678	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.43e-05	0.000674	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CYP2S1—psoriasis	4.35e-05	0.000662	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	4.33e-05	0.000658	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CXCL8—psoriasis	4.25e-05	0.000646	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—VEGFA—psoriasis	4.23e-05	0.000643	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—STAT3—psoriasis	4.19e-05	0.000636	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—NDUFA5—psoriasis	4.17e-05	0.000633	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	4.14e-05	0.00063	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—VEGFA—psoriasis	4.12e-05	0.000627	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—IL6—psoriasis	4.1e-05	0.000623	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CXCL8—psoriasis	4.09e-05	0.000622	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—STAT3—psoriasis	4.08e-05	0.00062	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—IL6—psoriasis	4e-05	0.000607	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.95e-05	0.000601	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.88e-05	0.00059	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCL20—psoriasis	3.88e-05	0.00059	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CYP2S1—psoriasis	3.79e-05	0.000576	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—LEP—psoriasis	3.78e-05	0.000574	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—APOE—psoriasis	3.78e-05	0.000574	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—TNF—psoriasis	3.62e-05	0.000551	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CYP2S1—psoriasis	3.54e-05	0.000538	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—TNF—psoriasis	3.53e-05	0.000537	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.53e-05	0.000537	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—NFKBIA—psoriasis	3.52e-05	0.000535	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CXCL8—psoriasis	3.46e-05	0.000526	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.44e-05	0.000523	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—CARM1—psoriasis	3.29e-05	0.0005	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.08e-05	0.000468	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—TP53—psoriasis	3.01e-05	0.000457	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCL20—psoriasis	2.94e-05	0.000447	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.94e-05	0.000447	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—IL6—psoriasis	2.92e-05	0.000445	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—TYK2—psoriasis	2.88e-05	0.000438	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—SOCS1—psoriasis	2.88e-05	0.000438	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—IL6—psoriasis	2.85e-05	0.000433	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.83e-05	0.00043	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—IL6—psoriasis	2.76e-05	0.000419	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—TYK2—psoriasis	2.75e-05	0.000418	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.75e-05	0.000418	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	2.64e-05	0.000401	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CXCL8—psoriasis	2.62e-05	0.000398	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.57e-05	0.00039	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—SOCS1—psoriasis	2.53e-05	0.000384	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CXCL8—psoriasis	2.51e-05	0.000382	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CARM1—psoriasis	2.51e-05	0.000382	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—TYK2—psoriasis	2.41e-05	0.000367	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CXCL8—psoriasis	2.39e-05	0.000364	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—IL6—psoriasis	2.39e-05	0.000363	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CYP2S1—psoriasis	2.34e-05	0.000355	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—JUN—psoriasis	2.33e-05	0.000355	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	2.31e-05	0.000351	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.28e-05	0.000347	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—NFKB1—psoriasis	2.25e-05	0.000342	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.2e-05	0.000335	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—SOCS1—psoriasis	2.14e-05	0.000325	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—LEP—psoriasis	2.13e-05	0.000324	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—APOE—psoriasis	2.13e-05	0.000324	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CARM1—psoriasis	2.13e-05	0.000323	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CXCL8—psoriasis	2.1e-05	0.000319	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—VEGFA—psoriasis	2.04e-05	0.00031	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—TYK2—psoriasis	2.04e-05	0.00031	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—CAT—psoriasis	2.02e-05	0.000308	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—STAT3—psoriasis	2.02e-05	0.000307	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.99e-05	0.000302	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.98e-05	0.000301	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.95e-05	0.000297	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.94e-05	0.000295	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—LEP—psoriasis	1.87e-05	0.000284	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—APOE—psoriasis	1.87e-05	0.000284	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.86e-05	0.000282	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CARM1—psoriasis	1.85e-05	0.000281	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.77e-05	0.00027	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.74e-05	0.000264	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CARM1—psoriasis	1.73e-05	0.000263	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TYK2—psoriasis	1.62e-05	0.000247	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—SOCS1—psoriasis	1.62e-05	0.000246	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.62e-05	0.000246	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—LEP—psoriasis	1.58e-05	0.00024	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—APOE—psoriasis	1.58e-05	0.00024	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—APOE—psoriasis	1.57e-05	0.000239	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—TYK2—psoriasis	1.54e-05	0.000235	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CAT—psoriasis	1.54e-05	0.000235	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—TP53—psoriasis	1.54e-05	0.000234	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.48e-05	0.000225	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—NFKBIA—psoriasis	1.47e-05	0.000223	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TYK2—psoriasis	1.42e-05	0.000217	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CXCL8—psoriasis	1.41e-05	0.000215	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—IL6—psoriasis	1.41e-05	0.000214	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PPARG—psoriasis	1.37e-05	0.000208	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—IL6—psoriasis	1.35e-05	0.000204	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CXCL8—psoriasis	1.34e-05	0.000204	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—JUN—psoriasis	1.32e-05	0.0002	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CAT—psoriasis	1.31e-05	0.000199	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—NFKB1—psoriasis	1.27e-05	0.000192	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CXCL8—psoriasis	1.24e-05	0.000189	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TYK2—psoriasis	1.2e-05	0.000183	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—APOE—psoriasis	1.2e-05	0.000182	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—APOE—psoriasis	1.2e-05	0.000182	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—LEP—psoriasis	1.2e-05	0.000182	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—IL6—psoriasis	1.18e-05	0.000179	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—JUN—psoriasis	1.15e-05	0.000175	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—VEGFA—psoriasis	1.15e-05	0.000175	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CARM1—psoriasis	1.14e-05	0.000173	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CAT—psoriasis	1.14e-05	0.000173	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—STAT3—psoriasis	1.14e-05	0.000173	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—NFKBIA—psoriasis	1.11e-05	0.000169	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—NFKB1—psoriasis	1.11e-05	0.000169	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CAT—psoriasis	1.06e-05	0.000162	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CXCL8—psoriasis	1.05e-05	0.000159	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PPARG—psoriasis	1.05e-05	0.000159	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—APOE—psoriasis	1.02e-05	0.000154	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—VEGFA—psoriasis	1.01e-05	0.000153	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—STAT3—psoriasis	9.97e-06	0.000152	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—IL6—psoriasis	9.97e-06	0.000152	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—JUN—psoriasis	9.75e-06	0.000148	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—NFKB1—psoriasis	9.38e-06	0.000143	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TYK2—psoriasis	9.12e-06	0.000139	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—APOE—psoriasis	8.85e-06	0.000135	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PPARG—psoriasis	8.85e-06	0.000134	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TP53—psoriasis	8.68e-06	0.000132	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—VEGFA—psoriasis	8.51e-06	0.000129	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—STAT3—psoriasis	8.43e-06	0.000128	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—APOE—psoriasis	8.27e-06	0.000126	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IL6—psoriasis	7.95e-06	0.000121	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CXCL8—psoriasis	7.94e-06	0.000121	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PPARG—psoriasis	7.71e-06	0.000117	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TP53—psoriasis	7.61e-06	0.000116	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—IL6—psoriasis	7.55e-06	0.000115	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—JUN—psoriasis	7.39e-06	0.000112	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PPARG—psoriasis	7.2e-06	0.000109	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—NFKB1—psoriasis	7.11e-06	0.000108	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CAT—psoriasis	7.02e-06	0.000107	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL6—psoriasis	6.97e-06	0.000106	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—VEGFA—psoriasis	6.45e-06	9.81e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TP53—psoriasis	6.43e-06	9.78e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—STAT3—psoriasis	6.39e-06	9.71e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL6—psoriasis	5.89e-06	8.95e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—APOE—psoriasis	5.45e-06	8.29e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TP53—psoriasis	4.88e-06	7.41e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PPARG—psoriasis	4.75e-06	7.22e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL6—psoriasis	4.46e-06	6.78e-05	CbGpPWpGaD
